Results 61 to 70 of about 122,145 (339)

The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD

Journal of Clinical Endocrinology and Metabolism, 2021
Context The burden of cirrhosis from nonalcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in the United States. This calls for greater awareness among endocrinologists, who often see but may miss the diagnosis in adults with obesity ...
Chandani Patel Chavez, K. Cusi, Sushma Kadiyala   +2 more
semanticscholar   +1 more source

Glucagon-like peptide-1 and its class B G protein-coupled receptors: A long march to therapeutic successes [PDF]

, 2016
Theglucagon-likepeptide (GLP)-1receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secretedfromthreemajor tissues inhumans,enteroendocrine L cells in the distal intestine, a cells in the ...
Adelhorst, Alastair J. H. Brown, Andersen, Avatapalle, Belin, Brown, Caihong Zhou, Chris de Graaf, Dan Donnelly, Davis, Dehua Yang, Denise Wootten, Denker, Dods, Drucker, Elahi, Ferguson, Gallwitz, Goodman, Green, Grynkiewicz, Gustavson, Göke, Hendrick, Heppner, Hjorth, Holst, Holst, Huang, Jendle, Jesper Lau, Jiayu Liao, Jiejie Deng, Jung-Mo Ahn, La Barre, Laurence J. Miller, Li, Locatelli-Hoops, Lund, Madeleine M. Fletcher, Ming-Wei Wang, Mojsov, Mojsov, Nauck, Nauck, Orskov, Orskov, Patrick M. Sexton, Pocai, Prentki, Rhodes, RICHARD DEQUAN YE, Sancho, Shiue, Steensgaard, Tang-Christensen, Tibaduiza, Tomkin, Unson, Wettergren, Widmann, Wild, Willard, Zunz   +63 more
core   +3 more sources

A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease

Therapeutics and Clinical Risk Management, 2022
Zeyu Xie, Jinjian Li, Sensen Yang, Weishang Deng, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Li J, Yang S, Deng W, Chen J
doaj  

An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders

Nature Mental Health
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel drugs approved for diabetes and obesity. They are acknowledged as a major scientific breakthrough.
Riccardo De Giorgi, A. Ghenciulescu, Oliwia Dziwisz, M. Taquet, A. Adler, I. Koychev, R. Upthegrove, Marco Solmi, R. McCutcheon, T. Pillinger, Phil Cowen, C. Harmer   +11 more
semanticscholar   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management

Advances in Medicine, 2023
Rates of obesity have risen over the past few decades. Subsequently, the popularity of the pharmaceutical weight-loss drug market has grown over the past few years to meet growing demand. Among the most commonly prescribed drugs for weight management, many are glucagon-like peptide-1 receptor agonists (GLP-1 agonists) which are also utilized for the ...
Magda Wojtara, Ashmita Mazumder, Yusra Syeda, Nikodem Mozgała   +3 more
openaire   +2 more sources

Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle [PDF]

, 2015
Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance.
Alloosh, Mouhamad, Bell, Lauren N., Chalasani, Naga, Dineen, Stacey L., Fullenkamp, Allison M., McKenney, Mikaela L., Schultz, Kyle A., Sturek, Michael   +7 more
core   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

Genetic aspects of type 1 glucagon peptide agonists clinical efficacy: A review

Терапевтический архив, 2023
A review of publications devoted to the analysis of genetic polymorphisms of the gene encoding the glucagon-like peptide type 1 receptor and some other genes directly and indirectly involved in the implementation of its physiological action is presented.
Evgenya L. Golovina, Ivan R. Grishkevich, Olga E. Vaizova, Iuliia G. Samoilova, Darja V. Podchinenova, Mariia V. Matveeva, Dmitry A. Kudlay   +6 more
doaj   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Comment. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? [PDF]

, 2014
Adam M.
A. M. Deane, Deane, Deane, Deane, M. Horowitz, Schwartz, Umpierrez   +6 more
core   +1 more source